https://doi.org/10.1016/j.apsb.2025.06.008
This new article publication from
Acta Pharmaceutica Sinica B, discusses filamenting temperature-sensitive mutant Z as a novel target for antibiotics development.
Filamenting temperature-sensitive mutant Z (FtsZ), a protein essential for bacterial cell division, is highly conserved across bacterial species but absent in humans, positioning it as a strategic target for the development of antibiotics. Significant efforts to identify FtsZ inhibitors—
via biochemical assays (
e.g., GTPase activity) and cellular approaches (
e.g., immunofluorescence)—have yielded over 100 natural products and synthetic compounds, whose cheminformatics clustering underscores a limited chemical diversity among the current scaffolds. Structural studies, including X-ray crystallography and cryo-electron microscopy, have resolved 97 FtsZ structures revealing conserved polymerization mechanisms and conformational plasticity, as exemplified by extremophile adaptations (
e.g.,
Shewanella benthica from the high-pressure environment of the Mariana Trench's Challenger Deep). However, clinical translation is hindered by weak binding affinities, inhibitory inefficacy, dynamic conformational flexibility, and evolving drug resistance linked to FtsZ's functional plasticity. To address these challenges, future efforts should be directed to resolve transient assembly intermediates, leveraging machine learning with high-throughput screening, and integrating structural biology with pharmacokinetic optimization. Multidisciplinary strategies combining these approaches hold promise for translating FtsZ-focused research into clinically viable therapies, addressing the critical unmet need posed by antibiotics resistance.
Keywords: FtsZ, Cell division, Drug target, Cryo-electron microscopy, Deepsea bacterium, Antibiotics
Graphical Abstract: available at
https://ars.els-cdn.com/content/image/1-s2.0-S2211383525004113-ga1_lrg.jpg
FtsZ, a pivotal bacterial cell division protein, is a potential therapeutic target for bacterial infections. This review explores opportunities, challenges, and structural insights for drug discovery against FtsZ, highlighting current advances and future directions.
# # # # # #
The Journal of the
Institute of Materia Medica, the Chinese Academy of Medical Sciences and the
Chinese Pharmaceutical Association.
For more information please visit
https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/
Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board
APSB is available on
ScienceDirect (
https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).
Submissions to
APSB may be made using
Editorial Manager® (
https://www.editorialmanager.com/apsb/default.aspx).
CiteScore: 24.3
Impact Factor: 14.6 (Top 6 journal in the category of Pharmacology and pharmacy)
JIF without self-citation: 13.8
ISSN 2211-3835
# # # # #
Ming-Wei Wang, Kaini Hang, Wei Han, Xin Li, Qingtong Zhou, Dehua Yang, FtsZ as a novel target for antibiotics development: Promises and challenges, Acta Pharmaceutica Sinica B, Volume 15, Issue 8, 2025, Pages 3978-3996, ISSN 2211-3835,
https://doi.org/10.1016/j.apsb.2025.06.008